Pubdate: Wed, 28 Jan 2015
Source: Oregonian, The (Portland, OR)
Copyright: 2015 The Oregonian
Contact:  http://www.oregonlive.com/oregonian/
Details: http://www.mapinc.org/media/324
Author: Noelle Crombie

PEDIATRICIANS CALL ON FEDS TO RECLASSIFY POT

The American Academy of Pediatrics this week weighed in on the 
classification of marijuana, urging the federal government to 
reclassify the drug to facilitate research.

The organization released a policy statement on marijuana, 
reaffirming its opposition to legalizing cannabis and expressing 
concern about the drug's harmful affects on young people. But the 
group also urged the government to move marijuana from its Schedule I 
status, where it's grouped with heroin and LSD, to Schedule 2, also 
considered dangerous but more accessible to researchers.

In the government's view, Schedule I drugs have a "high potential" 
for abuse and offer no medicinal value. Generally, drugs with 
Schedule I status are not open to research.

The Huffington Post reports:

The DEA is the federal agency that is primarily responsible for 
regulating controlled substances like marijuana. But the Food and 
Drug Administration, along with the National Institute on Drug Abuse, 
provides the DEA with recommendations about the appropriate level of 
restriction for various illicit substances.

The FDA is already engaged in a review of the medical evidence 
surrounding the safety and effectiveness of marijuana. The evaluation 
was initiated due to a request from the DEA, following a number of 
citizens' petitions asking for a review. According to the Controlled 
Substances Act, the government must consider eight factors when 
deciding the schedule under which a substance should be classified. 
These include its potential for abuse, the state of current 
scientific knowledge about the substance and its psychic or 
physiological dependence liability.

The FDA could not confirm to The Huffington Post how long the review 
process takes, but expressed support for AAP's move.
- ---
MAP posted-by: Jay Bergstrom